Cipla posts gloomy Q1FY17

Cipla has announced its Q1FY17 results on Friday after market hours. The company’s revenue has declined by 6.38 per cent to Rs 3594 crore in Q1FY17 as compared to same period in previous financial year. Its EBITDA has dropped by 42.06 per cent to Rs 611 crore in Q1FY17 on a yearly basis. Cipla’s EBITDA margin has contracted by 1046 basis points to 17 per cent in Q1FY17 as compared to same period in previous fiscal. The company’s net profit has decreased by 39.68 per cent to Rs 396 crore in Q1FY17 on a yearly basis.

On the segmental revenue front, Cipla has earned 99.45 per cent from Pharmaceuticals and remaining 0.55 per cent from a new venture during Q1FY17.

The share price of Cipla has declined by 1.26 per cent on bourses; and has closed at Rs 516.65 on an intraday basis.

Cipla’s business units include Active Pharmaceutical Ingredients (APIs), Respiratory medication and Cipla Global Access. The company is offering its services across five continents across the world. It offers its services in India, South Africa, Europe and North America, among others. Cipla offers over 1000 products across approximately 120 countries.